Changing Japanese Healthcare with AI and Medical Data! SoftBank and Tempus Establish New Company SB TEMPUS

In an era when one in two people will develop cancer in their lifetime, early detection and early treatment are key

Cancer has become the leading cause of death, and it is said that one in two people will develop cancer at least once in their lifetime. However, early detection and early treatment increases the likelihood of a complete cure.

U.S. Top Runner Tempus and SoftBank Group Establish Joint Venture

Tempus AI, Inc. ("Tempus"), a leading AI and precision medicine company, and SoftBank Group Corp. announced the establishment of a joint venture, SB TEMPUS Corporation, on June 27.

SB TEMPUS aims to provide three medical services

SB TEMPUS seems to plan to sequentially provide three medical services in Japan: [genetic testing], [collection and analysis of medical data], and [recommendation of treatment options using AI].
The world may be a different place in 5 or 10 years.

1. Gene testing: Optimal cancer treatment for each individual

SB TEMPUS will help find the best treatment for patients with the same cancer by conducting a genetic test to identify the characteristics of the patient's cancer.
If this system is realized, side effects and risks can be reduced to a greater extent than now. 2.

2. medical data collection and analysis: AI will change the future of medicine

SB TEMPUS will utilize AI to collect and analyze medical data from patients. This data includes molecular data, clinical data, pathology data, and medical imaging data.
The speed of AI development is tremendous and expectations are quite high.

3. recommendation of treatment options by AI: more options for patients

SB TEMPUS is likely to utilize AI to recommend the best treatment option for each patient. These recommendations are likely to include not only already approved drugs, but also advanced treatments in development.

Why Tempus is supported by the U.S. healthcare industry

Tempus is used by 2,000 hospitals in the U.S. for three reasons

Unparalleled volume of data and advanced AI analysis

Zero cost service for hospitals and physicians

High success rate: 96% of patients are presented with the best treatment option (which is quite accurate)

Impact of SB TEMPUS on Cancer Care in Japan

SB TEMPUS is expected to bring the following innovations to Japanese healthcare

Widespread use of genetic testing: Aiming for 1 million tests per year

Integration of data from core hospitals: Contribution to improving the quality of medical care in Japan

Discovery of new treatments by AI: Pathway to overcoming intractable diseases

Masayoshi Son: "AI is not for leading mankind to ruin. It is for people's happiness."

At the press conference, Masayoshi Son said, "The information revolution, including AI, AGI, and ASI, is not intended to lead mankind to ruin. Its greatest principle is for people's happiness, and we are going to do it for that purpose," he said.

SB TEMPUS aims to revolutionize healthcare in Japan and save many lives through the power of AI and medical data.

Stay tuned for more news as it develops.